retatrutide type 2 diabetes phase 2 trial hba1c 💉 A triple-action once-weekly injection can significantly lower blood sugar and body weight in people with diabetes, a new 3 shows. is part of an emerging generation Retatrutide Phase 2: Type 2

111 ReboucheC

Ipamorelin, because it is not associated with the receptor desensitisation reported with Hexarelin over continued exposure

According to Robert Kushner, an obesity researcher at Northwestern University Feinberg School of Medicine , who led one of the STEP studies, semaglutide is a "game-changer" for people with obesity

The response demonstrates dose-dependent GH release

Key findings from animal studies Superior body weight reduction compared to GLP-1 monoagonists in diet-induced obese rodent models Significant reduction in hepatic fat content in NASH models, suggesting relevance for metabolic liver disease research Improvements in lipid profiles (triglycerides, LDL cholesterol) beyond what was observed with GLP-1 monoagonism alone Evidence of increased energy expenditure supporting the glucagon receptor-mediated thermogenesis hypothesis Clinical Research Timeline (Updated Through 2026) Retatrutide has now progressed through Phase 3 clinical trials with three major readouts between December 2025 and May 2026, representing the most advanced clinical development of any triple hormone receptor agonist to date

Kosiborod MN, Petrie MC, Borlaug BA, Butler J, Davies MJ, Hovingh GK, et al